Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 99, Issue 1, Pages 92-100Publisher
WILEY-BLACKWELL
DOI: 10.1002/cpt.277
Keywords
-
Categories
Funding
- AHRQ HHS [R01HS023122, K08 HS023898, K08HS023898, R01 HS023122] Funding Source: Medline
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
- NIA NIH HHS [R01AG025152, R01 AG025152] Funding Source: Medline
- NIDDK NIH HHS [R01 DK102694, R01DK102694] Funding Source: Medline
Ask authors/readers for more resources
A drug-drug interaction (DDI) occurs when one or more drugs affect the pharmacokinetics (the body's effect on the drug) and/or pharmacodynamics (the drug's effect on the body) of one or more other drugs. Pharmacoepidemiologic studies are the principal way of studying the health effects of potential DDIs. This article discusses aspects of pharmacoepidemiologic research designs that are particularly salient to the design and interpretation of pharmacoepidemiologic studies of DDIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
